Accordingly, as both molecular signaling pathways are synergistically involved in tumor growth, combining epidermal growth factor (EGF) inhibition with a VEGF inhibitor such as ramucirumab is a rational treatment strategy in EGFR-mutant NSCLC. This evidence concerns the gene EGF and neoplasm.